

## PDCD1

### Human anti-PD-1 Receptor (Nivolumab) mAb

<b>Catalog No.</b>	CSB114A CSB114B	<b>Quantity:</b>	200 µg 1.0 mg
<b>Alternate Names:</b>	BMS-936558,MDX-1106,ONO-4538, Opdivo		
<b>Description:</b>	Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody that works as a checkpoint inhibitor, used to treat several types of cancer including, advanced (metastatic) non-small cell lung cancer (NSCLC), melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer .		
<b>Concentration:</b>	1.0 mg/ml		
<b>UniProt ID (target):</b>	Q15116		
<b>Source:</b>	CHO cell line		
<b>Isotype:</b>	Human IgG4 kappa		
<b>INN:</b>	Nivolumab		
<b>Specificity:</b>	Human PD-1 receptor		
<b>Biologic Activity:</b>	Blocks PD-L1 binding to the PD-1 receptor		
<b>Formulation:</b>	PBS, pH 7.5		
<b>Purity:</b>	> 95% as determined by SDS-PAGE		
<b>Reactivity:</b>	Human		
<b>Applications:</b>	Functional studies, ELISA		
<b>Storage &amp; Stability:</b>	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. <b>Avoid freeze/thaw cycles.</b>		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

